The stock may react positively to the strong financial turnaround and growth guidance, but traders should monitor the FDA dialogue on Joenja®'s pediatric expansion and upcoming Phase II readouts as key catalysts. The CRL introduces near-term regulatory risk that could limit upside despite strong commercial performance.
Price Chart
Executive Summary
Pharming Group reported strong full-year 2025 results with 27% revenue growth to $376.1 million, driven by RUCONEST® and Joenja®. The company achieved its first annual operating profit ($25.8 million) and positive operating cash flow ($54.7 million), while providing 2026 revenue guidance of $405–$425 million. However, a recent FDA Complete Response Letter for Joenja®'s pediatric label expansion introduces regulatory risk.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue increased 27% YoY to $376.1 million
- Achieved $25.8 million operating profit in 2025 vs. $8.6 million loss in 2024
- Net cash flow from operations was $54.7 million in 2025 vs. negative in 2024
- 2026 revenue guidance of $405–$425 million (8%–13% growth)
- FDA issued Complete Response Letter for Joenja® pediatric sNDA, requesting additional PK data
- Phase II readouts for leniolisib in broader PIDs expected in second half of 2026
Financial Impact
Revenue up 27% to $376.1M, operating profit turned positive at $25.8M, cash flow from operations $54.7M
Risk Factors
- FDA Complete Response Letter delays pediatric approval of Joenja®
- Foreign exchange volatility impacting financial results
- Execution risk in advancing pipeline, particularly FALCON study completion and readout
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254281 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Press Release | — | awaiting T+20 | — | — |
Sep 11, 2026 6w ago | Press Release | — | awaiting T+20 | — | — |
Aug 13, 2026 10w ago | Press Release | — | awaiting T+20 | — | — |
Jul 30, 2026 12w ago | Press Release | — | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | — | awaiting T+20 | — | — |
May 28, 2026 21w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 7, 2026 29w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers